Clinical trials: Positron Emission Tomography
Tumor, PD-L1
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
To evaluate the potential usefulness of 68Ga-NK224 positron emission tomography/computed tomography (PET/CT) for the evaluation of PD-L1 expression in primary and/or metastatic tumors, compared with histopathological results.
- Trial name
- NCT06754345
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
Prostatic Neoplasms
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
PyL, also known as [18F]DCFPyL, is a second-generation fluorinated prostate-specific membrane antigen (PSMA) targeted PET imaging agent.
- Trial name
- NCT03824275
- Testing
- 18F- DCFPyL PET/CT
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Columbia University
High-grade Glioma, Brain Metastases
A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors
The purpose of this study is to find out whether 68Ga-PSMA-11 PET/CT is effective in assessing tumor uptake (tumor activity seen in cancerous tissue) in participants with high-grade glioma/HGG or brain metastases.
- Conditions
- High-grade Glioma, Brain Metastases, Brain Metastases, Adult
- Trial name
- NCT06209567
- Testing
- 68Ga-PSMA-11 PET Scans
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervix Cancer, Endometrial Cancer
Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
This is a research study using Granulocyte Colony Stimulating Factor (GCSF) as a bone marrow stimulating agent for imaging to guide radiation treatment planning. G-CSF is a type of growth factor.
- Trial name
- NCT04514692
- Testing
- GCSF
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Stanford University
Solid Tumors, Cancer
Feasibility Study for Imaging of Peripheral Tumors With a High-Resolution PET Imaging System
The goal of this clinical research study is to learn if using the PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of the body that has, or is suspected to have cancer will give researchers the same or…
- Trial name
- NCT01008930
- Testing
- HR PEM Scan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Solid Tumor
MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
The purpose of this Expanded Access Program (EAP) is to allow use of the investigational therapeutic agent, MNPR-101-PCTA-177Lu, for treatment of urokinase plasminogen activator receptor (uPAR)-positive solid tumors identified…
- Conditions
- Cancer, Solid Tumor, Solid Tumor Cancer, Oncology
- Trial name
- NCT06980519
- Testing
- MNPR-101-PCTA-177Lu
- Where
- United States
- Sponsor
- Monopar Therapeutics
Primary Liver Cancer, Liver Metastasis
Evaluation of Preoperative Investigations in Patients With Liver Cancer
The aim of the study is to evaluate the diagnostic procedures emission tomography in combination with a CT scan (PET/CT) and endoscopic ultrasonography (EUS) in the preoperative evaluation of resectability of patients with…
- Trial name
- NCT00408122
- Testing
- PET/CT scan and EUS
- Where
- Denmark
- Volunteers
- 77 people
- Sponsor
- Odense University Hospital
Non-ischemic Cardiomyopathy, Dilated Cardiomyopathy (DCM)
Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.
Non-ischemic cardiomyopathies (NICM) represent a heterogeneous group of pathologies characterized by absence of obstructive disease of the epicardial coronary vessels and distinct structural and functional changes of the…
- Conditions
- Non-ischemic Cardiomyopathy, Dilated Cardiomyopathy (DCM), Hypertrophic Cardiomyopathy (HCM), Restrictive Cardiomyopathy
- Trial name
- AINICM (NCT06607471)
- Testing
- Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation, Support treatment, cardiac medical treatment, aetiology-specific treatment
- Where
- Italy
- Volunteers
- 15,000 people
- Sponsor
- Scientific Institute San Raffaele
Solid Tumor
Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors
To study the normal physiological distribution of the probe 124I-EV in human body and its ability to detect overexpression of Nectin-4 in tumor lesions.
- Trial name
- NCT05322512
- Testing
- 18F-FDG
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Lung Cancer (NSCLC), Lung Cancer (SCLC)
PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor
The objective of this study is to construct a noninvasive approach using radiolabbled peptide 68Ga-cPP-BCH PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to…
- Conditions
- Lung Cancer (NSCLC), Lung Cancer (SCLC), Melanoma (Skin Cancer), Melanoma Metastatic
- Trial name
- NCT07442292
- Volunteers
- 40 people
- Sponsor
- Peking University Cancer Hospital & Institute
Neuroendocrine Tumors
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
This study has 3 steps and not everyone will have all 3 steps done. The overall goals are to see if a new experimental drug is safe to image (step 1) and treat neuroendocrine tumors (step 2 and 3).
- Trial name
- NCT02609737
- Testing
- PET/CT Imaging, 68Ga-DOTA-JR11, 177Lu-DOTA-JR11
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
Men with a history of prostate cancer may be in this study. Subjects recommended for a prostatectomy or oligometastectomy will undergo PET/CT imaging using a novel radiotracer [18F]FTT to evaluate PARP-1 activity in known or…
- Trial name
- NCT03334500
- Testing
- [18F]FluorThanatrace, Poly(ADP Ribose) Polymerase 1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Frontotemporal Lobar Degeneration, Dementia
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia
This study will use positron emission tomography (PET) imaging to measure a receptor in the brain that is involved in inflammation.
- Trial name
- NCT00613119
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Congenital Hyperinsulinism
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
The goal of this project is to determine the role of FDOPA/PET as a pre-operative diagnostic imaging procedure for differentiating focal and diffuse forms of congenital hyperinsulinism and locating focal lesions in the pancreas…
- Trial name
- DOPA PET (NCT04205604)
- Testing
- 18F-Fluoro Dopa Imaging
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Miguel Pampaloni
Depression
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
Background: Major depressive disorder (MDD) is a psychiatric condition. People with MDD have occasional bouts of depressive symptoms; these bouts are called major depressive episodes (MDEs).
- Trial name
- NCT05703685
- Testing
- Lung scan, Apremilast, 18F-PF-06445974
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Parkinson's Disease
Parkinson's Disease Evaluated by PET and the Effect of Memantine
Purpose of study: To investigate whether the NMDA antagonist Memantine has a substantial effect of brain metabolism in patients with Parkinson's disease (PD), using Positron Emission Tomography (PET).
- Trial name
- NCT00375778
- Testing
- memantine (drug)
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- University of Aarhus
Prostate Cancer
64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer
This research project is testing a new compound which may potentially detect specific cancer lesions in men with prostate cancer.
- Trial name
- NCT05286840
- Testing
- 64Cu-SAR-bisPSMA
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Luke Nordquist, MD
Healthy Volunteers
Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects
The overall goal of this protocol is to evaluate [18F]MNI-968 (aka PF-06730110) as a D1 receptor targeted radiopharmaceutical.
- Trial name
- NCT03082768
- Testing
- [18F]MNI-968
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Tauopathies
Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C HY-2-15. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with…
- Trial name
- NCT06032026
- Testing
- 11C-HY-2-15 PET, brain MRI, Amyloid PET scan
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
High-grade Glioma of the Brain
PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?
The aim of the study is to define preferential sites of tumour recurrence by observing tracer uptake in the tumour in sequential PET images with 18F-fluoromethylcholine (and perfusion MR, see also below).
- Trial name
- NCT00628940
- Testing
- PET images with 18F-fluoromethylcholine
- Where
- Belgium
- Volunteers
- 90 people
- Sponsor
- University Ghent
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.